{"id":"18f-2-fluoro-2-deoxy-d-glucose","safety":{"commonSideEffects":[{"rate":null,"effect":"Radiation exposure"},{"rate":null,"effect":"Allergic reaction to tracer"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL1880349","moleculeType":"Small molecule","molecularWeight":"164.16"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) is taken up by cells with high glucose metabolism, particularly cancer cells and inflamed tissues. The fluorine-18 isotope undergoes positron decay, allowing detection via positron emission tomography (PET) imaging. This enables visualization and localization of metabolically active lesions for diagnostic and staging purposes.","oneSentence":"18F-FDG is a glucose analog labeled with fluorine-18 that accumulates in metabolically active tissues and emits positrons for PET imaging detection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:56:19.627Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"PET imaging of malignant neoplasms (oncology)"},{"name":"PET imaging of brain disorders (dementia, epilepsy)"},{"name":"PET imaging of cardiac viability assessment"}]},"trialDetails":[{"nctId":"NCT07166549","phase":"PHASE1","title":"Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2026-06","conditions":"B Cell Malignancies, B-cell Leukemia, B Cell Lymphoma","enrollment":12},{"nctId":"NCT02237872","phase":"","title":"Detection of Brown Adipose Tissue by Magnetic Resonance Imaging","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2015-01-20","conditions":"Obesity, Brown Adipose Tissue","enrollment":8},{"nctId":"NCT03032601","phase":"NA","title":"Physiological Effects of N-Acetyl Cysteine in Patients With Multiple Sclerosis","status":"ENROLLING_BY_INVITATION","sponsor":"Thomas Jefferson University","startDate":"2017-01-05","conditions":"Multiple Sclerosis","enrollment":55},{"nctId":"NCT02637479","phase":"NA","title":"Treatment of Opioid-refractory Pain (WHO Level III) by Pituitary Radiosurgery","status":"UNKNOWN","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2015-12","conditions":"Any Cancer With Multiple Bone Metastases","enrollment":40},{"nctId":"NCT02489604","phase":"PHASE2","title":"Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors","status":"TERMINATED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2013-12","conditions":"Neuroendocrine Tumors","enrollment":70},{"nctId":"NCT03740126","phase":"NA","title":"Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2018-10-25","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":750},{"nctId":"NCT00375830","phase":"PHASE2","title":"Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases","status":"COMPLETED","sponsor":"Stanford University","startDate":"2006-01","conditions":"Cancer","enrollment":114},{"nctId":"NCT06081270","phase":"","title":"Prospective Study on Resistance-associated Mutations in Metastatic Lung Cancer","status":"UNKNOWN","sponsor":"University of Milano Bicocca","startDate":"2021-12-12","conditions":"Lung Cancer","enrollment":20},{"nctId":"NCT03513042","phase":"","title":"Early Response Evaluation of Proton Therapy by PET-imaging in Squamous Cell Carcinoma Located in the Head and Neck","status":"TERMINATED","sponsor":"Leiden University Medical Center","startDate":"2021-01-21","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":12},{"nctId":"NCT02208544","phase":"NA","title":"FDG-PET/CT in Evaluation of Cytological Indeterminate Thyroid Nodules to Prevent Unnecessary Surgery (EfFECTS)","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2015-07-16","conditions":"Thyroid Nodule, Thyroid Neoplasms","enrollment":132},{"nctId":"NCT04831619","phase":"PHASE3","title":"Contribution of PET (Positron Emission Tomography) Scans for the Preoperative Assessment of Symptomatic Endometriosis Lesions: TEP-ENDORUN","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire de la Réunion","startDate":"2022-05","conditions":"Endometriosis","enrollment":10},{"nctId":"NCT04615156","phase":"PHASE3","title":"18F-2-fluoro-2-deoxy-D-glucose in Positron Emission Tomography Computed Tomography","status":"NOT_YET_RECRUITING","sponsor":"Eastern Health, Canada","startDate":"2020-11-01","conditions":"Solitary Pulmonary Nodule, Oncology, 18F-2-fluoro-2-deoxy-D-glucose","enrollment":10000},{"nctId":"NCT03481101","phase":"NA","title":"WHENII - Early Response Evaluation With FDG-PET/CT and Liquid Biopsy in Patients With NSCLC","status":"UNKNOWN","sponsor":"Rigshospitalet, Denmark","startDate":"2018-02-28","conditions":"Non Small Cell Lung Cancer, Circulating Tumor Cell, Circulating Tumor DNA","enrollment":60},{"nctId":"NCT02970851","phase":"","title":"Bosentan in Myocardium Metabolism and Perfusion Measured by 18F-FDG and 82Rb PET/CT on PAH and CTEPH","status":"TERMINATED","sponsor":"University of Lausanne Hospitals","startDate":"2013-04","conditions":"Myocardial Dysfunction, Endothelial Dysfunction","enrollment":2},{"nctId":"NCT04253574","phase":"","title":"Comparison of PET/CT and Ultrasound in Staging of Malignant Melanoma","status":"COMPLETED","sponsor":"University of Basel","startDate":"2014-09-01","conditions":"Malignant Melanoma","enrollment":258},{"nctId":"NCT04117139","phase":"NA","title":"The Diagnostic Value of PET/MRI in Head and Neck Cancer","status":"UNKNOWN","sponsor":"Odense University Hospital","startDate":"2019-10-01","conditions":"Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Lymph Node Metastases","enrollment":142},{"nctId":"NCT01215318","phase":"NA","title":"FDG Uptake in Vaginal Tampons is Due to Urine","status":"COMPLETED","sponsor":"Irene Burger","startDate":"2010-02-02","conditions":"Cancer","enrollment":44},{"nctId":"NCT03041090","phase":"NA","title":"Patterns and Prevalence of FDG Extravasation in PET/CT Scans","status":"COMPLETED","sponsor":"St. Louis University","startDate":"2016-03","conditions":"Intravenous Infiltration","enrollment":133}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"18F-2-fluoro-2-deoxy-D-glucose","genericName":"18F-2-fluoro-2-deoxy-D-glucose","companyName":"Eastern Health, Canada","companyId":"eastern-health-canada","modality":"Small molecule","firstApprovalDate":"","aiSummary":"18F-FDG is a glucose analog labeled with fluorine-18 that accumulates in metabolically active tissues and emits positrons for PET imaging detection. Used for PET imaging of malignant neoplasms (oncology), PET imaging of brain disorders (dementia, epilepsy), PET imaging of cardiac viability assessment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}